Adamas Pharmaceuticals Inc (NASDAQ:ADMS) – Stock analysts at Svb Leerink issued their Q1 2019 EPS estimates for shares of Adamas Pharmaceuticals in a research note issued to investors on Monday, March 4th. Svb Leerink analyst M. Goodman anticipates that the specialty pharmaceutical company will earn ($1.31) per share for the quarter. Svb Leerink also issued estimates for Adamas Pharmaceuticals’ Q2 2019 earnings at ($0.85) EPS, Q3 2019 earnings at ($0.78) EPS, Q4 2019 earnings at ($0.81) EPS, FY2019 earnings at ($3.65) EPS, FY2020 earnings at ($2.10) EPS, FY2021 earnings at ($1.20) EPS, FY2022 earnings at $0.30 EPS and FY2023 earnings at $2.40 EPS.
Get Adamas Pharmaceuticals alerts:ADMS has been the topic of several other reports. Zacks Investment Research lowered Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 27th. HC Wainwright set a $40.00 price objective on Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Monday, January 14th. BidaskClub raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, February 25th. Cowen lowered Adamas Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $30.00 to $15.00 in a report on Tuesday. Finally, Leerink Swann assumed coverage on Adamas Pharmaceuticals in a report on Monday, November 12th. They issued an “outperform” rating and a $20.00 price objective on the stock. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the stock. Adamas Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $23.88.
Shares of ADMS opened at $7.87 on Thursday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 8.74 and a current ratio of 8.95. Adamas Pharmaceuticals has a 12 month low of $7.42 and a 12 month high of $32.90.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Monday, March 4th. The specialty pharmaceutical company reported ($1.06) EPS for the quarter, beating the consensus estimate of ($1.36) by $0.30. Adamas Pharmaceuticals had a negative return on equity of 106.74% and a negative net margin of 617.27%. The company had revenue of $13.32 million for the quarter, compared to analyst estimates of $13.30 million.
Several large investors have recently modified their holdings of ADMS. First Mercantile Trust Co. boosted its stake in shares of Adamas Pharmaceuticals by 43.2% in the fourth quarter. First Mercantile Trust Co. now owns 5,765 shares of the specialty pharmaceutical company’s stock worth $49,000 after acquiring an additional 1,740 shares during the last quarter. Advisor Group Inc. boosted its stake in shares of Adamas Pharmaceuticals by 252.0% in the fourth quarter. Advisor Group Inc. now owns 6,300 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 4,510 shares during the last quarter. Pacer Advisors Inc. acquired a new stake in shares of Adamas Pharmaceuticals in the third quarter worth approximately $104,000. Barclays PLC boosted its stake in shares of Adamas Pharmaceuticals by 87.6% in the fourth quarter. Barclays PLC now owns 17,387 shares of the specialty pharmaceutical company’s stock worth $148,000 after acquiring an additional 8,118 shares during the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Adamas Pharmaceuticals in the fourth quarter worth approximately $161,000. 79.76% of the stock is currently owned by hedge funds and other institutional investors.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Further Reading: The mechanics of the bid-ask spread in trading
No comments:
Post a Comment